Physician’s Profile

Lisa S. Wiechmann, MD

Affiliations: 
NewYork-Presbyterian/Columbia
Board Certificates: 
Surgery
Expertise: 
Breast Surgery
Breast Cancer
Honors: 
Included in Castle Connolly’s Top Doctors, 2017.
Susan G. Komen Breast cancer Foundation Fellowship (2006-2007). Institution/ Organization: Baylor College Of Medicine - Research. Date: September 2006-June 2008
Susan G. Komen for the Cure-AACR Scholar-in-Training Award. Institution/ Organization: San Antonio Breast Cancer Symposium. Date: December 2008.
Breast Cancer Alliance Award / Sponsored Fellow. Insitution/ Organization: Memorial Sloan Kettering / Breast Cancer Alliance Award. Date: July 2008-June 2009.
Winner SSO Annual Meeting Poster Contest.  Insitution/ Organization: Society of Surgical Oncology’s 62nd Annual Cancer Symposium. Date: March 2009.
ASCO/AACR Vail Methods in Clinical Cancer Research Workshop Scholarship. Date: September 2009.
Faces of Respect. Institution/ Organization: Montefiore Medical Center. Date: 2011-13.
Greenwich Hospital Quality Award Winner, July 2015.
About: 

Dr. Wiechmann is a board certified surgeon specializing in breast cancer, who was recognized with honors by the Breast Cancer Alliance, the Susan G. Komen for the Cure foundation and the Society of Surgical Oncology.

Many patient–driven awards have recognized a gifted surgeon who takes pride in her relationship with patients and their families, while offering exceptional personalized cancer care, Dr Wiechmann’s dedication. These include the “Faces of Respect” Award at Montefiore Medical Center (2011-2013) and the Greenwich Hospital Quality Award (2015). Her peers recently selected Dr Wiechmann as a Castle Connolly Top Doctor, a nationally ranked service whose mission is to help consumers find the best healthcare; she has been listed in the “Guide to America’s Top Surgeons” for the past 3 years.

Dr. Wiechmann is a breast surgeon with over 10 years of experience at the Comprehensive Breast Center of the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia, a multi-site, multi-disciplinary entity that incorporates the legacy of innovation and trust associated with the Columbia University Medical Center. She works closely with a multi-disciplinary team including radiologists, medical oncologists, radiation oncologists, plastic surgeons and other breast cancer support staff. Her goal is to make patient and family experience as simple, thorough, and streamlined as possible. Dr Wiechmann approaches each patient in a personal, kind, and compassionate way and believes in shared decision-making and teamwork. She speaks English, Spanish, and Italian fluently and can conduct the consultation in any of those languages.

In the clinic, Dr. Wiechmann's interests include triple negative breast cancer (ER, PR, and HER2 negative), the genetic and familial predisposition to breast cancer, and disparities in cancer treatment and outcomes.

Dr Wiechmann, who was born and raised in Florence, Italy, received her medical degree Magna Cum Laude at Universita' Degli Studi Di Firenze Facolta' Di Medicina e Chirurgia in Florence, Italy.

She completed a General Surgery Residency at TUFTS, St. Elizabeth's Medical Center in Boston followed by a research fellowship in the prestigious laboratory of Dr Kent Osborne and Dr Rachel Schiff, at the Lester and Sue Smith Breast Center of the Dan L. Duncan Cancer Center at Baylor College of Medicine, in Houston, Texas. At Baylor, her research focused on the preclinical development of therapies targeting the HER2 receptor; her work was recognized by Komen/AACR. Dr Wiechmann’s work has been published in many surgical and the Breast Cancer Alliance, the Susan G. Komen for the Cure foundation and the Society of Surgical Oncology have repeatedly recognized oncology publications and her with awards for her research and scholarship.

After completing her research at Baylor, Dr Wiechmann was the recipient of the Breast Cancer Alliance award that funded her clinical fellowship at Memorial Sloan-Kettering Cancer Center, which led to her participation in the prestigious ASCO/AACR (American Society for Clinical Oncology/American Association for Cancer Research) course, Methods in Clinical Cancer Research.

Publications: 
Isolation of Mouse and Human Tumor-Associated Macrophages. Cassetta L, Noy R, Swierczak A, Sugano G, Smith H, Wiechmann L, Pollard JW. Adv Exp Med Biol. 2016;899:211-29. doi: 10.1007/978-3-319-26666-4_12. PMID: 27325269.
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. Breast Cancer Res Treat. 2014 Jul;146(1):145-52. doi: 10.1007/s10549-014-3008-5. Epub 2014 Jun 6. PMID: 24903226.
Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer. Yeo EJ, Cassetta L, Qian BZ, Lewkowich I, Li JF, Stefater JA 3rd, Smith AN, Wiechmann LS, Wang Y, Pollard JW, Lang RA. Cancer Res. 2014 Jun 1;74(11):2962-73. doi: 10.1158/0008-5472.CAN-13-2421. Epub 2014 Mar 17. PMID: 24638982.
Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. Peterson EA, Pectasides E, Shabbeer S, Wiechmann L, Sparano JA, Kenny PA. Exp Hematol Oncol. 2013 Sep 8;2(1):25. doi: 10.1186/2162-3619-2-25. PMID: 24010672.
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. Cancer Res. 2013 Aug 1;73(15):4885-97. doi: 10.1158/0008-5472.CAN-12-4081. Epub 2013 Jun 4. PMID: 23737486.
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R. Clin Cancer Res. 2011 Mar 15;17(6):1351-61. doi: 10.1158/1078-0432.CCR-10-1905. Epub 2010 Dec 7. PMID: 21138857.
Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema. Goldberg JI, Wiechmann LI, Riedel ER, Morrow M, Van Zee KJ. Ann Surg Oncol. 2010 Dec;17(12):3278-86. doi: 10.1245/s10434-010-1155-4. Epub 2010 Jun 24. PMID: 20574774.
Presenting features of breast cancer differ by molecular subtype. Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M. Ann Surg Oncol. 2009 Oct;16(10):2705-10. doi: 10.1245/s10434-009-0606-2. Epub 2009 Jul 11. PMID: 19593632.
The molecular journey from ductal carcinoma in situ to invasive breast cancer. Wiechmann L, Kuerer HM. Cancer. 2008 May 15;112(10):2130-42. doi: 10.1002/cncr.23430. Review. PMID: 18383519.
Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Arpino G, Wiechmann L, Osborne CK, Schiff R. Endocr Rev. 2008 Apr;29(2):217-33. doi: 10.1210/er.2006-0045. Epub 2008 Jan 23. Review. PMID: 18216219.
DCIS of the breast: a look towards discovery and advancements in the field. Kuerer HM, Wiechmann LS, Pusztai L. Ann Surg Oncol. 2007 Nov;14(11):3033-4. Epub 2007 Aug 21. No abstract available. PMID: 17705090.